Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Provenge Off-Label Use Is Key CMS Concern In NCA, Dendreon Says

Executive Summary

In its ongoing national coverage analysis of Dendreon's Provenge (sipuleucel-T), the Centers for Medicare and Medicaid Services is taking a close look at Medicare coverage for off-label use of the novel prostate cancer vaccine, according to the company

You may also be interested in...



Provenge Data Not Supportive Of Off-Label Uses, MEDCAC Finds

The existing clinical data on Dendreon's prostate cancer vaccine Provenge cannot be "generalizable" to off label uses, most members of the Medicare Evidence Development and Coverage Advisory Committee agreed at a Nov. 17 meeting.

Parallel Review Could Deter NCD, Medicare Exec Says; Provenge A Case In Point?

Overlapping FDA product approval and Medicare coverage reviews could help biopharmaceutical firms avoid a later Medicare national coverage determination for a new therapy, CMS Coverage and Analysis Group Director Louis Jacques suggested during a webinar sponsored by Avalere Health Sept. 30.

Parallel Review Could Deter NCD, Medicare Exec Says; Provenge A Case In Point?

Overlapping FDA product approval and Medicare coverage reviews could help biopharmaceutical firms avoid a later Medicare national coverage determination for a new therapy, CMS Coverage and Analysis Group Director Louis Jacques suggested during a webinar sponsored by Avalere Health Sept. 30.

Related Content

Topics

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel